Cargando…
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboure...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376844/ https://www.ncbi.nlm.nih.gov/pubmed/32700670 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001260 |
| _version_ | 1783562110114988032 |
|---|---|
| author | Harvala, Heli Mehew, Jennifer Robb, Matthew L Ijaz, Samreen Dicks, Steven Patel, Monika Watkins, Nicholas Simmonds, Peter Brooks, Tim Johnson, Rachel Gopal, Robin Roberts, David J Zambon, Maria Thomas, Stephen MacLennan, Sheila Estcourt, Lise Brailsford, Su Baklan, Hatice Tettmar, Kate Kellington, Jeremy Sell, Joanne Miflin, Gail |
| author_facet | Harvala, Heli Mehew, Jennifer Robb, Matthew L Ijaz, Samreen Dicks, Steven Patel, Monika Watkins, Nicholas Simmonds, Peter Brooks, Tim Johnson, Rachel Gopal, Robin Roberts, David J Zambon, Maria Thomas, Stephen MacLennan, Sheila Estcourt, Lise Brailsford, Su Baklan, Hatice Tettmar, Kate Kellington, Jeremy Sell, Joanne Miflin, Gail |
| author_sort | Harvala, Heli |
| collection | PubMed |
| description | Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels. |
| format | Online Article Text |
| id | pubmed-7376844 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Centre for Disease Prevention and Control (ECDC) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73768442020-07-28 Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 Harvala, Heli Mehew, Jennifer Robb, Matthew L Ijaz, Samreen Dicks, Steven Patel, Monika Watkins, Nicholas Simmonds, Peter Brooks, Tim Johnson, Rachel Gopal, Robin Roberts, David J Zambon, Maria Thomas, Stephen MacLennan, Sheila Estcourt, Lise Brailsford, Su Baklan, Hatice Tettmar, Kate Kellington, Jeremy Sell, Joanne Miflin, Gail Euro Surveill Rapid Communication Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels. European Centre for Disease Prevention and Control (ECDC) 2020-07-16 /pmc/articles/PMC7376844/ /pubmed/32700670 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001260 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| spellingShingle | Rapid Communication Harvala, Heli Mehew, Jennifer Robb, Matthew L Ijaz, Samreen Dicks, Steven Patel, Monika Watkins, Nicholas Simmonds, Peter Brooks, Tim Johnson, Rachel Gopal, Robin Roberts, David J Zambon, Maria Thomas, Stephen MacLennan, Sheila Estcourt, Lise Brailsford, Su Baklan, Hatice Tettmar, Kate Kellington, Jeremy Sell, Joanne Miflin, Gail Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title | Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title_full | Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title_fullStr | Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title_full_unstemmed | Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title_short | Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 |
| title_sort | convalescent plasma treatment for sars-cov-2 infection: analysis of the first 436 donors in england, 22 april to 12 may 2020 |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376844/ https://www.ncbi.nlm.nih.gov/pubmed/32700670 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001260 |
| work_keys_str_mv | AT harvalaheli convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT mehewjennifer convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT robbmatthewl convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT ijazsamreen convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT dickssteven convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT patelmonika convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT watkinsnicholas convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT simmondspeter convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT brookstim convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT johnsonrachel convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT gopalrobin convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT robertsdavidj convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT zambonmaria convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT thomasstephen convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT maclennansheila convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT estcourtlise convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT brailsfordsu convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT baklanhatice convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT tettmarkate convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT kellingtonjeremy convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT selljoanne convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 AT miflingail convalescentplasmatreatmentforsarscov2infectionanalysisofthefirst436donorsinengland22aprilto12may2020 |